Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
Type:
Application
Filed:
January 18, 2023
Publication date:
September 21, 2023
Applicants:
MEMORIAL SLOAN-KETTERING CANCER CENTER, EVIVE BIOTECHNOLOGY (SHANGHAI) LTD
Inventors:
Marcel VAN DEN BRINK, Alan HANASH, Caroline LINDEMANS, Tom TANG
Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 ?g/kg to about 200 ?g/kg (such as about 10 ?g/kg to about 45 ?g/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.
Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
Type:
Grant
Filed:
December 23, 2019
Date of Patent:
January 31, 2023
Assignees:
MEMORIAL SLOAN-KETTERING CANCER CENTER, EVIVE BIOTECHNOLOGY (SHANGHAI) LTD
Inventors:
Marcel Van Den Brink, Alan Hanash, Caroline Lindemans, Tom Tang
Abstract: The present invention relates to methods of preventing and/or treating necrotizing enterocolitis or other intestinal inflammations using an IL-22, a dimer or a multimer thereof.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
November 29, 2022
Assignees:
Evive Biotechnology (Shanghai) Ltd, University Of Pittsburgh—Of The Commonwealth System Of Higher Education
Inventors:
Jay Kennedy Kolls, Misty Lynn Good, Xiaoqiang Yan